Abstract. This report demonstrates a T-cell receptor (Tcr) restriction fragment length polymorphism, defined by a Tcrb-V6
Introduction
Data on many of the HLA associations with autoimmune diseases have suggested the presence of other genetic factors, probably outside the major histocompatibility complex (MHC). The antigen-specific T-cell receptor (Tcr),
The nucleotide sequence data reported in this paper have been submitted to the GenBank nucleotide sequence database and have been assigned the accession numbers M67511 for V6.1A and M67512 for V6.1B. Address correspondence and offprint requests to: David N. Glass, Special Treatment Center for Juvenile Arthritis, Children's Hospital Medical Center, Elland and Bethesda Avenues, Pay 1-129, Cincinnati, OH 45229-2899, USA which recognizes antigen only in the context of HLA molecules, seems a likely source of such effects. Interest has therefore focused on the Tcr c~ chain (Tcra) and 3 chain (Tcrb) genes. The human Tcrb gene complex is located on chromosome 7. Transcription of the polypeptide follows rearrangement of discontinuous gene segments encoding variable (10, diversity (D) , joining (J), and constant (C) regions in a manner analogous to the transcription of immunoglobulins. DNA sequence and Southern blot hybridization analyses have subdivided the Tcrb-V gene segments into 20 groups, or subfamilies, defined on the basis of nucleotide sequence homology (Barth et al. 1985) . Each subfamily contains between one and ten members. Gene segments of different subfamilies are highly interspersed and may be spaced more than five kilobases (kb) apart (Lai et al. 1989) . The c~ chain gene complex, located on chromosome 14, structurally resembles the 3 chain complex (Davis and Bjorkman 1988) .
Several studies have reported Tcr gene restriction fragment length polymorphisms (RFLPs) in a variety of autoimmune disorders, but were limited to description of C region RFLPs which carried low relative risks (Millward et al. 1987; Demaine et at. 1989; Tebib et at. 1990) . Recent family studies, demonstrating lack of linkage disequilibrium between V and C region genes of both Tcra and Tcrb gene complexes (Charmley et al. 1988; 990), indicate that further study should be directed primarily towards V region genes, because they are the genes that most directly influence antigen-MHC recognition. Tcr-V region genes may be studied indirectly by RFLP and directly by sequencedependent methods.
The present study has demonstrated the possible contribution of a Tcrb-V region RFLP to the inherited predisposition of a form of juvenile rheumatoid arthritis (JRA) for which HLA associations have been established.
T h e a b s o l u t e c o r r e l a t i o n o f this R F L P w i t h c o d i n g seq u e n c e variability in an a d j a c e n t Tcrb-V6.1 g e n e has b e e n d e m o n s t r a t e d . F i n a l l y , a n d m o s t i m p o r t a n t l y , t h e a s s o c i ation o f a h u m a n a u t o i m m u n e d i s e a s e w i t h allelic s e q u e n c e v a r i a t i o n in a v a r i a b l e r e g i o n o f the T c r /3 c h a i n is d e m o n s t r a t e d .
Materials and methods
Patientpopulation. One hundred and twenty-six unrelated Caucasian patients, well characterized with respect to HLA markers, were studied. All had early-onset pauciarticular juvenile rheumatoid arthritis (EOPA-JRA) as defined by the American College of Rheumatology criteria (Cassidy et al. 1986 ). Such patients are characterized by a pauciarticular onset (affecting four or fewer joints) in the first six months of disease, predominance of females (88%), presence of antinuclear antibody (ANA), and the development of a chronic form of iridocyclitis. All patients had disease onset before the age of 8 years. The control group of 207 unrelated Caucasian individuals resembled the disease population with respect to geographic and ethnic (European) origin, both carrying a strong Northern European (German) ethnic component. This control series has been described previously .
Tcrprobes. The human Tcrb cDNA clone 4D1, a 1 kb cDNA isolated from the human T-cell tumor line HPB-MLT, contains the V6.1, D, J, and C2 regions of the Tcrb chain (Jones et al. 1984; Leiden and Strominger 1986) . This cDNA was subcloned in pUC19, and a specific V region probe was derived by polymerase chain reaction (PCR) amplification of the V region sequence using specific primers. The probe was labeled by random priming with [a-32p]-deoxynucleotide triphosphates (3000 Ci/mmol; New England Nuclear, Boston, MA) to specific activities ranging from 5 x 10 s to i x 109 cpm/~tg of DNA (Feinberg and Vogelstein 1983) .
Tcrb-V6.1 associated RFLP. This polymorphism was detected as previously described . The Tcrb-V6.1/Bgl II probe/enzyme combination defines a bi-allelic locus with polymorphic bands of 12.5 and 5.7 kb.
DNA amplification and sequencing. Bgl II restriction enzyme-digested genomic DNA, derived from five unrelated individuals homozygous for the 12.5 kb fragment and from five unrelated individuals homozygous for the 5.7 kb fragment, was run on agarose gels. Gel slices containing the polymorphic fragments were excised, isolated by phenol/chloroform extraction, and used as template for PCR amplification of the RFLPrelated Tcrb-V6 gene member. The sequences of oligonucleotides to be used as Tcrb Vfi. 1 gene-specific primers were determined from the published sequence of the 4D1 eDNA that had served as the Tcrb-V6 gene probe. The primers were derived from the 5' end and 3' end of the 4D1 cDNA V region sequence, (I. 5' CCGAATTCGATGG-GAGCTCAGGTGTGATC 3" sense; and II. 5' CCGAATTCACA-GAGATACACGGCTGAGTCC 3' antisense) so that the fragment amplified by these primers would include most of the exon encoding PCR reaction products were digested with Eco RI restriction enzyme (Pharmacia, Piscataway, NJ) in agarose (to cleave the 5' ends of the primers) and extracted with phenol/chloroform. The digested DNA was ligated into an Eco RI-digested M13 mpl9 vector, transformed into Escherichia coil JM109, and plated. Clones were screened by in situ plaque hybridization with the random-primer 32p-labeled Tcrb-V6 cDNA probe. Purified DNA from positive clones was sequenced by the dideoxy chain termination method (Sequenase, US Biochemicals, Cleveland, OH). All sequences were determined on both strands. At least three clones per DNA restriction fragment were sequenced in order to confirm sequence variation.
Dot-blot analysis. Members of the patient and control populations (patients n= 83, controls n = 99) were oligotyped for Tcrb-V6.1 gene allelic sequence variants. After PCR amplification of 1 ~tg of genomic DNA using Tcrb-V6 gene specific primers, 2 ~tl of the amplified material was dot-blotted onto Nylon-66 membrane filters (0.1 ~tm pore size) (Schleicher and Schuell, Keene, NH). The following Tcrb-V6.1 gene allele-specific oligonucleotide (ASO) probes were synthesized (III. 5" CTGCCCAACGATCGGTT 3' and IV. 5' CACAGAGCGGGGG-GACT 3' designated V6.1N and V6.1R respectively detecting sequence V6.1A. Two other probes (V.) 5" CTGCCCAAAGATCGGTT 3' and VI. 5' CACAGAGCAGGGGGACT 3' were designated V6.1K and V6.1Q, respectively and detected sequence V6. IB. These probes were labeled with [a-32P]-ATP and polynucleotide kinase and hybridized with the blots overnight at 37 °C in 6 × standard sodium citrate (SSC), 1 ×Denhardt's solution and 50 ~tg/ml low relative mass DNA. Blots were washed twice in 6 × SSC at room temperature, and 5 rain at 57 °C for probe III, at 53 °C for probe IV, at 55 °C for probe V, and at 49 °C for probe VI, followed by exposure to Kodak X-omat film for 2 h. Positive and negative controls consisted of PCR-amplified genomic DNA from individuals homozygous for either the 5.7 kb or the 12.5 kb Bgl II fragment, whose Tcrb-V6.1 gene alleles had been characterized previously by DNA sequencing and dot-blot analysis. Additional controis included phage supernatants, each sample containing a different Tcrb-V6.1 gene allele.
HLA typing, HLA-DR antigens in our entire study population were typed serologically according to standard techniques using antisera that included those tested by the eighth, ninth, and tenth Histocompatibility Workshops (Mittal et al. 1968) . In addition, a previous study which included some subjects evaluated in the present study, had identified HLADQAl*0101 individuals as a distinct cohort of patients at increased risk for progression of polyarticular joint disease and a lower risk for the iridocyclitis of JRA (Van Kerckhove et al. !991) . HLA-DQwl a-chain alleles were therefore typed using allele-specific oligonucleotide probes following PCR amplification of the second exon of the DQ c~-chain using specific primers . Typing results were available for 121 patients with EOPA-JRA and 202 controls.
Statistics. Statistical analysis was carried out using the chi-square test with one degree of freedom unless otherwise specified with adjustments for the number of comparisons made. P values were adjusted for multiple comparison using the Bonferroni correction.
Results

Tcrb-Vb gene R F L P , H L A and disease.
T h e d i s t r i b u t i o n o f Tcrb-V6.1/Bgl II R F L P g e n o t y p e s a n d allelic f r e q u e ncies did n o t differ significantly b e t w e e n the total p a t i e n t a (Fig. 1) . Sequence V6.1B has not, to our knowledge, been described previously. It differs from sequence V6.1A by two single bp substitutions, an adenine for a cytosine at position 132 of the amplified fragment and an adenine for a guanine at position 197 of the amplified fragment. These substitutions occurred as paired changes in all 70 clones examined. Since the 4D 1 cDNA is a partial length clone lacking 54 nucleotides at the 5' end of the Vgene coding sequence, these changes would result in substitution of a lysine (AAA) for an asparagine ( Correlation of allelic sequence variation with Tcrb-V6.1 gene RFLP. The sequence data obtained from clones allowed the design and use of allele-specific oligonucleotide (ASO) probes that hybridized to regions spanning the newly identified substitutions (Fig. 1) thus distinguishing sequences V6.1A and B. In view of previous reports documenting frequent recombination within the Tcra and b-V regions (Seboun et al. 1989; Charmley et al. 1990 ) such oligonucleotide probes were initially used to ascertain the correlation between the Tcrb-V6.1/Bgl II RFLP and the two V6.1 gene sequences in individuals carrying different RFLP genotypes. PCRamplified genomic DNA samples were initially analyzed with the V6.1 N and K probes defining sequences V6.1A and B, respectively (see Materials and methods). Samples from all individuals homozygous for the 5.7 kb Bgl II fragment (patient n = 38; control n = 28) hybridized only to the V6.1N probe indicating the presence of sequence V6.1A, while samples from all 12.5 kb homozygotes (patients n= 14; controls n= 16) hybridized only to the V6.1Kpro-bes, indicating the presence of sequence V6.1B (Fig. 2) . Additional individuals, heterozygous at the Bgl II RFLP locus (patient n = 37; control n = 34), were oligotyped and shown to possess both Tcrb V6.1 sequence variants. Tcrb V6.1A and Vg. 1B therefore represent allelic variants that correlate absolutely with the 5.7 kb and 12.5 kb Bgl II RFLP alleles, respectively. Results obtained with the V6.1N and V6.1K probe pair were verified in additional dot-blot analyses on 36 samples, using the V6.1R and V6.1Q probes (Fig. 1) . 
Tcrb-V6.1 allelic sequence variations and disease. The
Discussion
This study demonstrates the association of a Tcrb V region gene polymorphism with one subtype of JRA in the context of a particular HLA class II allele, HLA-DQAl*0101. These findings thus support a possible contribution by this Tcrb-V gene to at least one human autoimmune disease, EOPA-JRA. Sequence data obtained on PCR-amplified DNA derived from restriction fragment templates that contain Tcrb V6.1 genes, indicated proximity of the Bgl II RFLP to a V6.1 gene locus containing two V6.1 gene allelic variants. One such variant, V6.1B, represents a previously undescribed V6.1 gene sequence.
Comparison of the V6.1A and B gene sequences indicates a high degree of sequence conservation, consistent with two previous reports. Robinson (1989) described a single bp substitution within the coding region of the Tcrb V1 gene, and Li and co-workers (1990) reported two bp substitutions in the coding region of the Tcrb-V6. 7 gene. Additional sequence variability of the V6.1 gene at the extreme 5' and 3' ends cannot be excluded however. The 4D1 cDNa (Leiden and Strominger 1986 ) used as the Tcrb V6.1 gene probe in the present study is a partial length clone, lacking 54 nucleotides at the 5' end of the coding region sequence. Furthermore, the 3' V6.1 gene primer annealed to the 4D1 cDNA template nine nucleotides upstream of the V-D region junction. Sequences at the extreme 5' and 3' ends of the V6.1 gene coding sequence were therefore not included in our PCR-amplified fragment. However, the finding of only two V6.1 gene alleles is consistent with previous studies demonstrating limited allelism in human and murine Tcr-V genes (Robinson 1989; Li et al. 1990; Pullen et al. 1990; Posnett 1990) .
The similarities between framework regions of Tcr molecules and immunoglobulins permit the construction of structural models of the Tcr molecule based on known immunoglobulin structure (Chothia et al. 1988 ). The two nucleotide differences between allelic variants V6.1A and V6.1B result in non-conservative amino acid substitutions at positions 62 and 84 of the Tcrb chain. Both positions represent sites of intermediate residue variability and each appears to be located in the loops between b-sheet framework strands. Position 62 is thought to lie close to the Tcr equivalent of the second hypervariable region of Ig (Davis and Bjokman 1988) and therefore may influence antigen/MHC recognition.
Consideration of the role played by Tcrb-V6.1 genes in the pathogenesis of EOPA-JRA must include the observation that HLA-DQAl*0101_ patients are more likely to possess a V6.1B gene and less likely to possess a V6.1A gene in their genomic repertoire. A possible etiologic role for the V6.1B allele in disease susceptibility would be consistent with previous reports assigning a dominant role for T cells expressing particular variable genes in animal models of autoimmunity (Urban et al. 1988; Acha-Orbea et al. 1988) . Alternatively, the decreased frequency of the V6.1A gene segment in HLA-DQAl*0101 patients could represent a "hole" in the available Tcr repertoire. Individuals lacking the V6.1A gene segment may be unable to eliminate foreign antigen(s) presented by HLA-DQAI*0101; the antigen(s) may then act as an inciting arthritogen. Another possibility consistent with the concept of a "hole in the repertoire" is that the V6.1A gene segment encodes a suppressor receptor on T cells. Several epitopes derived from type II collagen have been shown to stimulate suppressor T cells that confer protection against murine collagen-induced arthritis (Myers et al. 1989) . Such suppressor T cells may be necessary to prevent establishment of chronic disease following the inciting antigenic stimulus or to prevent progression of disease to a polyarticular form.
These considerations do not adequately account for the occurrence of disease in HLA-DQAI*OI01 individuals who are either heterozygous for the V6.1 gene alleles or homozygous for V6.1A. HLA (Gulwani-Akolkar et al. 1991) and non-HLA influences on thymic selection of expressed Tcrs in the periphery may result in preferential expression of V6.1B rather than V6.1A in heterozygotes.
Thus, HLA-DQAI*OI01, additional HLA alleles, non-HLA alleles, and/or endogenous superantigens on thymic epithelial cells could positively select T cells bearing V6.1B in preference to V6.1A or, alternatively, could prevent the maturation of T cells bearing V6.1A (if such T cells are potentially self-reactive; Zhou et al. 1991) . Additional considerations, of particular relevance to V6.1A homozygotes, are the possible contributory roles of additional Tcrb-V gene segments, of Tcra-V genes, and of sequence variation in the D and J regions of the Tcr/3 chain.
Other reports support the suggestion that gene complementation between Tcrb-V genes and HLA-DQ alleles may contribute to disease chronicity in arthritis patients. In the murine model of collagen arthritis, development of disease is dependent on the presence of a Tcr haplotype carrying a full complement of Tcrb V genes and an allelic variant of the I-A chain carried on the H2 q haplotype (Banerjee et al. 1988; Holmdahl et al. 1989) . The concept of Tcr/HLA gene complementation has also received experimental support from studies of animal models of systemic lupus (Yanagi et al. 1986; Ghatak et al. 1987) and of a subgroup of systemic lupus erythematosus (SLE) patients with anti-Ro antibodies (Frank et al. 1990 ).
The advantage of segregating patients on an immunogenetic basis was supported by our ability to isolate individuals who were at increased risk of suffering progressive disease. Further insight into immunopathologic mechanisms will require studies of Tcr expression in diseased tissue. Such investigation may provide the rationale for the development of highly specific immunotherapeutic strategies based on Tcr epitope-specific reagents.
